

Therapies for AL Amyloidosis: 2024

Traditional Antibodies	Alkylating Agents	Proteasome Inhibitors	Steroids	IMiDs and CELMoDs	Bispecific Abs and Cellular Therapies	Novel Therapies	Anti-Fibril Agents
Daratumumab (Darzalex)	Cyclophosphamide (Cytoxan)	Bortezomib (Velcade)	Dexamethasone (Decadron)	Thalidomide (Thalomid)	Teclistamab (Tecvayli)	Venetoclax (Venclexta)	Anselamimab (CAEL101)
Isatuximab (Sarclisa)	Melphalan (Alkeran)	Ixazomib (Ninlaro)	Prednisone	Lenalidomide (Revlimid)	Elranatamab (Elrexfio)		Birtamimab (NEOD001)
Elotuzumab (Empliciti)	High-Dose Melphalan	Carfilzomib (Kyprolis)		Pomalidomide (Pomalyst)	Linvoseltamab (REGN4548)		AT-02 (PAR-IgG)
Belantamab (Blenrep)	Bendamustine (Treanda)			Iberdomide (CC220)	ABBV-383		AT-03 (PAR-SAP)
				Mezigdomide (CC-92480)	CART Cells (BCMA-Directed)		
					AT-06 (PAR CAR-M)		
					Talquetamab (Talvey)		
Dara	Cy	Bor	D				
Daratumumab (Darzalex)	Cyclophosphamide (Cytoxan)	Bortezomib (Velcade)	Dexamethasone (Decadron)				

Bold Black: FDA-Approved
 Standard Black: Available Off Label
 Standard Red: Investigational